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Abstract  
BACKGROUND: The aberrant activation of Wnt signalling pathway may be a common denominator for the 
development of thyroid tumorigenesis. It was announced that the loss of E-cadherin rather than β-catenin 
mutation represents a crucial event in determining the degree of differentiation of thyroid carcinomas. 
AIM: The aim of the study was to evaluate the expression of E-cadherin and β-catenin in the thyroid cancer tissue 
and to correlate these data with some histological and clinical parameters of the tumours.
 
MATERIAL AND METHODS: We investigated 112 patients, having thyroid tumours – papillary, follicular, 
anaplastic and oncocytic carcinomas immunohistochemically with antibodies against E-cadherin and β-catenin. 
Survival analyses were done. 
 
RESULTS: E-cadherin expression was focally retained in the tumour cell membranes and the tumour cell 
cytoplasm of the papillary, follicular and oncocytic thyroid cancers, weather in anaplastic cancers it was almost 
lost (p = 0.0042, and р = 0.019, respectively, Fisher's Exact Test). The expression of β-catenin in tumour 
cytoplasm and membrane in papillary cancers was higher as compared to that in the other tumours (p = 0.111, 
and р = 0.0104, respectively). 
CONCLUSION: Not surprisingly, the presence of aberrant expression of E-cadherin and β-catenin in thyroid 
cancer has been associated with better patients' prognosis and better differentiated tumour histology.  
 
 
 
 
 
Introduction 
 
Thyroid cancer is one of the most frequent 
endocrine tumours at present and appears to be a 
particularly interesting neoplastic process in which 
some authors cited as major prognostic markers: age, 
sex, tumour size, hormonal regulation, iodine 
exchange, genetic polymorphisms, in anti-tumor 
immunity violations. This tumour is usually slow in 
growth, and fatal cases are rare, except for anaplastic 
carcinomas which have a rapid progression and 
dissemination [1]. Papillary carcinoma is the most 
common thyroid neoplasm representing about 80% of 
all thyroid malignancies [2], while follicular and 
anaplastic cancers are quite rare. The oncocytic 
thyroid tumour, originating from C-cells in the thyroid 
gland is usually benign and might have malignant 
behaviour.
 
Different factors - cellular and molecular play 
a role in development and progression of thyroid 
cancer. A dominant role of Wnt/β-catenin signalling in 
the proliferation of normal and neoplastic thyrocytes 
was reported [3]. The aberrant activation of the Wnt-
signaling pathway may be a common denominator for 
the development of tumours and strongly involved in 
thyroid tumorigenesis [4]. β-Catenin was originally 
described as an element of the E-cadherin/catenin 
complex. It is, however, an element of the Wnt 
signalling pathway and β-catenin may be tumorigenic 
[5]. β-Catenin is a multifunctional protein that plays an 
important role in signal transduction. In normal resting 
cells, it is mainly localised to the adherent junctions, 
while free cytosolic-β-catenin is recruited to a 
"destruction" complex that includes Axin, the tumour 
suppressor adenomatous polyposis coli (APC) and 
glycogen synthase kinase 3 (GSK3β). When the 
pathway is activated β-catenin is stabilised, that 
results in its nuclear accumulation and interaction with 
T-cell factor/lymphoid enhancer factor (TCF/LEF) or 
other transcription factors, and activation of genes 
required for cell proliferation (c-Myc and cyclin D1) [3]. 
Mutations in genes coding the proteins participating in 
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the regulation of β-catenin turnover (GSK3β, APC, 
AXIN) cause disturbance of the process of β-catenin 
protein degradation and its increase in the cellular 
cytoplasm [6].
 
Cadherin’s act as Ca
2+
- dependent adhesion 
molecules in the cell-cell adherence junction, a 
specialised region of the plasma membrane that is 
connected with cytoskeletal actin filaments. Cadherin 
molecules are integral membrane glycoproteins 
having a single transmembrane domain. The 
extracellular domain of E-cadherin is composed of five 
cadherin domains (EC1 to EC5) [7]. The cytoplasmic 
undercoat proteins for cadherins have been named 
catenins. β-Catenin interacts with cadherins through 
its cytoplasmic domain, which exhibits the strongest 
degree of homology between different members of the 
cadherin family. α-Catenin connects the E-cadherin 
and β-catenin complex to actin filaments. The 
interaction between cadherins and cytoskeletal 
proteins through catenins confer stability on the cell-
cell adherent junctions. These observations 
suggested the possibility that suppression of E-
cadherin activity triggers the release of cancer cell 
from primary cancer nests [5, 7]. 
The expression of E-cadherin and β-catenin in 
thyroid cancer was investigated mainly in 
immunohistochemical panels for differential diagnosis 
between different thyroid malignancies [8, 9]. Other 
investigators correlated the expression of both 
proteins with some clinical and histological 
parameters and tumour progression [9]. It was 
announced that the loss of E-cadherin rather than β-
catenin mutation represents a crucial event in 
determining the degree of differentiation of thyroid 
carcinomas [8, 10].
 
In this study, we used immunohistochemistry 
with anti-E-cadherin and anti-β-catenin antibodies to 
determine their various expressions in different 
epithelial thyroid malignancies and to determine their 
correlation with some parameters of tumour 
progression and overall survival data. 
 
 
Materials and Methods 
 
Patients 
For this retrospective study, we investigated 
112 patients (22 men and 90 women) mean age 57.9 
years (from 30 to 78 years). These thyroid cancer 
patients had been surgically treated for a period of 17 
years (from 1998 to 2015) in the University Hospital of 
Stara Zagora, Bulgaria. The patients were followed up 
until 01st January 2016 year. The overall survival data 
were used only for papillary thyroid cancers since the 
group was largest. Tumors were divided into four 
groups: papillary thyroid cancer (PTC) (n = 69) and 
follicular variant of papillary thyroid cancer (FVPTC) (n 
= 10), follicular thyroid cancer (FTC) (n = 13), 
anaplastic thyroid cancer (ATC) (n = 10) and oncocytic 
carcinoma (OC) (n = 10). Deeper invasion (higher pT 
staging) and advanced stages (stage III or IV) were a 
more frequent event in ATC and OTC than in PTC and 
FTC (p < 0.0001, and p = 0.010, respectively). Lack of 
tumour capsule was more often detected in 
specimens from ATC and OTC than from PTC and 
FTC (p = 0.008) (Table 1). Tumor staging was defined 
as 45.5% (n = 51) for the Ist stage, 14.3% (n = 16) for 
the IInd stage, 16.1% (n = 18) for the IIIrd stage and 
2.7% (n = 3) for the IVth stage. 
 
Immunohistochemistry 
Biopsy specimens were treated for routine 
histology (staining with hematoxylin and eosin) and for 
immunohistochemistry. Samples were fixed in 10% 
formalin, included in paraffin and the sections were 
5mm thick. For antigen retrieval, the deparaffination 
was done in hot xylene, at 56°C. Blocking of 
endogenous peroxidase was performed with 1.2% 
hydrogen peroxide solution in methanol for 30 
minutes. The specificity of the immune response is 
determined by substituting primary antibody with 
normal mouse serum. The duration of incubation with 
primary antibody and normal mouse serum was 
overnight at room temperature. The sections were 
counterstained with Mayer's hematoxylin for better 
visualisation of the DAB reaction product and then 
mounted with entering an for light microscopy. The 
antibodies used were the following: monoclonal 
mouse anti-human E-cadherin (M3612) both from 
DAKO A/S, Denmark, and anti-beta-catenin-Mhb 
(C19220) from Transduction Laboratories, USA. 
 
Evaluation of E-cadherin/β-catenin 
expression  
It was evaluated semi quantitatively as 
negative – (-); low – (-/+); and high – (++/+++). E-
cadherin immune reaction was evaluated in tumour 
cytoplasm and membranes, and β-catenin – in tumour 
cytoplasm, membranes and nuclei.
 
 
Statistical analysis 
Statistical analyses were performed using 
SPSS software package (SPSS, Inc., Chicago, IL, 
USA) and STATVIEW. The descriptive statistical 
tests, including the mean, standard deviation, and 
median, were calculated according to the standard 
methods. The associations E-cadherin/β-catenin 
expression and clinicopathological parameters were 
assessed by 
2
 Test. P < 0.05 was considered to be 
statistically significant. Survival plots were drawn by 
the Kaplan–Meier test and survival periods were 
compared by log-rank test.  
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Results 
 
Immunohistochemical study 
Expression of E-cadherin. We observe high 
expression in the cytoplasm and cell membrane in 
PTC and FTC and lower expression in the cytoplasm 
in OC. Patients with ATC showed low expression. 
 
Level of expression of E-cadherin and β-
catenin 
In PTC, OC and FTC the positive expression 
of E-cadherin in tumor membrane is more frequent 
(87.5%, 71.4% and 75% respectively) compared with 
ATC, where it is 25% (p = 0.0042). In membranes of 
PTC tumor expression of E-cadherin, more often is 
higher (+ + / + + +) (68.75%) compared with that in the 
OC, FTC and ATC (28.6%, 25% and 12.5%, 
respectively) (p = 0.0065). 
Expression of E-cadherin in tumor cytoplasm 
in a PTC is often high (+ + / + + +) (59.4%) compared 
with that in the OC, FTC and ATC (14.3%, 25% and 
12.5%, respectively) (p = 0.019). A tendency of higher 
expression of β-catenin in the cytoplasm in tumor PTC 
(66.7%) compared with FTC (33%) and absence of 
expression in ATC (0%, p = 0.111). 
 
Figure 1: Expression of β-catenin. the β-catenin immune response 
in tumour cytoplasm and membrane. 1) β-catenin positive 
expression in FTC X 200. 2) β-catenin positive expression in PTC X 
100. Expression of E-cadherin. E-cadherin immune response in 
tumour cytoplasm and membrane. 3) E-cadherin positive 
expression in OC X 200. 4) E-cadherin positive expression in PTC 
X 200. 5) E-cadherin positive expression in FTC X 200. 6) E-
cadherin positive expression in PTC X 200 
Observed was statistically more frequent high 
expression of β-catenin in tumour membrane in PTC 
(83.3%), while in other tumours, the expression of β-
catenin in tumour membranes is weak indicative (p = 
0.0104). All tumors showed low expression of β-
catenin in tumor nucleus (2 = 1.298, p = 0.730) 
(Figure 1). 
 
Comparing the level of expression with 
clinical data 
Comparing the expression of E-cadherin in 
tumour cytoplasm and the development of 
metastases, it was obtained that in 100% of the 
tumours with an expression of E-cadherin there were 
no metastases, (2 = 3.6, p = 0.058). 
Comparing the expression of E-cadherin in 
tumour membrane with tumour stage in patients with 
PTC turns out that 80.8% of tumours in stage I and II 
express E-cadherin in tumour membrane, while 50% 
of tumours in stage III and IV express E-cadherin (2 
= 3.41, p = 0.065) (Table 1). 
Table 1: Clinical data and histological and pathological 
characteristics of the tumour specimens according to the 
thyroid tumour type
 
Characteristics 
PTC 
N (%) 
FVPTC 
N (%) 
FTC 
N (%) 
ATC 
N (%) 
OTC 
N (%) 
p-value 
Age (mean±SD) 54.17±14.48 53.00±12.08 56.67±9.59 59.40±12.05 56.62±8.52 0.718* 
Gender 
    males 
    females 
 
9  (13.0) 
60(87.0) 
 
2  (20.0) 
8 (80.0) 
 
5 (38.5) 
8 (61.5) 
 
3 (30.0) 
7 (70.0) 
 
3 (30.0) 
7 (70.0) 
 
0.316** 
pT classification 
   T1-T2 
   T3-T4 
 
 
51 (91.1) 
5  (8.9) 
 
 
8  (80.0) 
2  (20.0) 
 
 
8 (72.7) 
3 (27.3) 
 
 
4 (40.0) 
6 (60.0) 
 
 
10 (100) 
0 (0) 
 
<0.000
1** 
Lymph node 
metastases 
    no 
    yes 
 
54 (96.4) 
2 (3.6) 
 
10 (100) 
0 (0) 
 
13 (100) 
0 (0) 
 
9 (90) 
1 (10) 
 
8 (80.0) 
2 (20.0) 
 
0.214** 
Distant metastases 
    no 
    yes 
 
69 (100) 
0   (0) 
 
10 (100) 
0 (0) 
 
13 (100) 
0 (0) 
 
10 (100) 
0 (0) 
 
9 (90.0) 
1 (10.0) 
 
0.065** 
pTNM staging 
     I stage 
     II stage 
     III stage 
     IV stage 
 
 
35 (62.5) 
14 (25.0) 
7 (12.5) 
0 (0) 
 
 
8 (72.7) 
2 (18.2) 
0 (0) 
0 (0) 
 
 
8 (72.7) 
0 (0) 
2 (18.2) 
1 (9.1) 
 
 
3 (30) 
1 (10) 
6 (60) 
0 (0) 
 
 
6 (60.0) 
1 (10.0) 
2 (20.0) 
1 (10.0) 
 
0.005** 
Capsule invasion 
Non capsular 
Capsular 
 
      9 (18.0) 
51 (82.0) 
 
9 (18.0) 
51 (82.0) 
 
5 (45.5) 
6 (54.5) 
 
7 (70.0) 
3 (30.0) 
 
5 (50.0) 
5 (50.0) 
 
0.008** 
* - ANOVA test; ** - 2 test 
 
There was no significant difference in β-
catenin expression between other clinical data, except 
for high expression in 73% of tumours in stage I and II 
compared with low expression of the catenin in the 
tumor in stage III and IV (2 = 3.59, p = 0.046). 
 
Overall survival in the group of patients 
with PTC 
Complete clinical and survival data were 
available from the Oncological archives for 56 of the 
patients. The patients were followed-up until 01st 
January 2016 year. At the end of the follow-up period 
there were 42 patients alive, as 30 of them with PTC 
(3/37), 6 with FTC (6/7), 3 with ATC (3/6) and 3 with 
OC (3/6). The medial survival period for all patients 
was 104.41 months, ranging from 1.64 to 197.07 
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months. Patients with PTC had a median survival of 
104.27 months (12.76 – 182.28 months), those with 
FTC –median of 123.38 months (18.15-197.08 
months); with ATC – median of 71.85 months (1.64-
163.86 months), and patients with OTC – median 
survival of 116.00 months (7.93 – 192.86 months). 
Due to the very small number of patients with some 
types of thyroid cancer, we performed survival 
analyses only in the group of patients with PTC. 
Samples with the presence of expression of E-
cadherin tumour membrane show a tendency for 
longer overall survival than those with absent 
expression (p = 0.072) (Figure 2).  
 
Figure 2: Kaplan-Mayer survival plot for overall survival (OS) after 
surgical therapy of patients with PTC according to the expression of 
E-cadherin (Log-rank test) 
 
 
Discussion 
 
Beta-catenin is involved in the regulation of 
gene expression as a mediator of the Wnt-signaling 
pathway. The expression and intracellular localisation 
of beta-catenin are altered in many types of cancers. 
Beta-catenin acts as an integral component of 
adherence junctions in addition to being a component 
of the Wnt-signaling. Beta-catenin links to epithelial 
cadherin, a major cell-cell adhesion molecule, with 
two other catenin members (α and γ) at pericellular 
membrane [11]. In our study, we found high 
expression of β-catenin in tumour membrane in PTC 
while in other tumours, the expression of β-catenin in 
tumour membranes is weak indicative.
 
E-cadherin is normally expressed in the 
thyroid gland and represents the main cell-cell 
adhesion molecule of the thyroid follicular cells. This 
cadherin is necessary for normal epithelial function, 
and it is responsible for calcium assisted cell 
adhesion. It can prevent the invasion of malignant 
tumours, and its synthesis in malignant cells is 
reduced. Epithelial cadherin levels in malignant 
tumours are variable and reduced [9]. E-cadherin has 
a significant function in intercellular adhesion of 
epithelial cells, the establishment of epithelial 
polarisation, glandular differentiation and stratification. 
Down-regulation of E-cadherin expression has been 
observed in some carcinomas and is usually 
associated with advanced stage and progression. The 
antibody is useful for the identification of E-cadherin-
positive cells in normal and neoplastic tissues. In our 
study, we found that highly differentiated epithelial 
carcinomas (PTC, FTC, OC) of the thyroid gland 
express in greater cell adhesion marker E-cadherin 
compared with non-differentiated anaplastic 
carcinomas. The low expression of E-cadherin in PTC 
confirms the results of Soares at al. 1997 and Brabant 
et al. 1993 [6, 18] who observed a reduction of this 
cadherin in a PTC compared with normal tissue. In 
our investigation, there was a tendency for statistical 
significance in E-cadherin expression between highly 
differentiated thyroid cancers (high expression) and 
anaplastic cancers (low expression). Also in our study, 
we found that tumours expressing E-cadherin in 
tumour cell cytoplasm develop metastases with very 
small probability. Erdem at al. 2011 [9] found the same 
results, generally, the presence of E-cadherin in 
tumour epithelium correlated with the absence of 
metastases and local invasion. Similar results were 
reported from Rocha et al. 2003 [10] and other 
author’s [12-14] who observed that in patients with 
over 30% E-cadherin staining, local recurrence and 
distant metastasis were rarely seen.  
In our investigation, there was a tendency for 
statistical significance of E-cadherin expression in 
tumour membrane with tumour stage in patients with 
PTC. We found that in stage I and II expression of E-
cadherin are high, while in stage III and IV the 
expression is less. The E-cadherin/catenin and its 
associated complexes participate in tumour 
development as suppressors or stimulators of growth, 
differentiation and invasion. Consequently, tumors 
which express E-cadherin can serve as a quality mark 
for their staging. This cadherin is also involved in 
adhesion between epithelial cells, and it seems to 
have a protective role in cancer since its loss is 
associated with tumour progression and metastases 
formation in a series of different cancers [12, 15, 16]. 
It has been proposed that reduced aberrant 
expression of E-cadherin is critical for the 
pathogenesis and biological behaviour of certain 
thyroid cancers [17-19]. It was possible that E-
cadherin expression was lost as an epiphenomenon 
of tumour dedifferentiation, rather than being a true 
pathogenic factor [20-24]. The role of adhesion factors 
in thyroid malignancies may be superior in 
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comparison with cell proliferation. Not surprisingly, the 
presence of aberrant expression of E-cadherin and β-
catenin in thyroid cancer has been associated with 
better patients' prognosis and better differentiated 
tumour histology.
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